Next Article in Journal
New Drug Regulations in France: What Are the Impacts on Market Access? Part 2—Impacts on Market Access and Impacts for the Pharmaceutical Industry
Previous Article in Journal
Benefits of Probabilistic Sensitivity Analysis—A Review of NICE Decisions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 1
Issue 1
10.3402/jmahp.v1i0.22799
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Delay and Restricted Access of New Molecules in Turkey Compared to the United States and European Union

by
Toros Şahin
*,
Atakan Yeşil
and
Türker Topcu
Sanofi-aventis Ltd. Sti, Buyukdere Cad. No: 193, Levent, Istanbul, Turkey
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2013, 1(1), 22799; https://doi.org/10.3402/jmahp.v1i0.22799
Submission received: 10 September 2013 / Revised: 21 October 2013 / Accepted: 23 October 2013 / Published: 15 November 2013

Abstract

Objective: This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007–2013. Methods: The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after 1 January 2007, worldwide and marketing authorization approval after 1 January 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia. Results: Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%). Conclusion: The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).
Keywords: launch; access to medicine; Turkish pharmaceutical market; new molecules launch; access to medicine; Turkish pharmaceutical market; new molecules

Share and Cite

MDPI and ACS Style

Şahin, T.; Yeşil, A.; Topcu, T. Delay and Restricted Access of New Molecules in Turkey Compared to the United States and European Union. J. Mark. Access Health Policy 2013, 1, 22799. https://doi.org/10.3402/jmahp.v1i0.22799

AMA Style

Şahin T, Yeşil A, Topcu T. Delay and Restricted Access of New Molecules in Turkey Compared to the United States and European Union. Journal of Market Access & Health Policy. 2013; 1(1):22799. https://doi.org/10.3402/jmahp.v1i0.22799

Chicago/Turabian Style

Şahin, Toros, Atakan Yeşil, and Türker Topcu. 2013. "Delay and Restricted Access of New Molecules in Turkey Compared to the United States and European Union" Journal of Market Access & Health Policy 1, no. 1: 22799. https://doi.org/10.3402/jmahp.v1i0.22799

APA Style

Şahin, T., Yeşil, A., & Topcu, T. (2013). Delay and Restricted Access of New Molecules in Turkey Compared to the United States and European Union. Journal of Market Access & Health Policy, 1(1), 22799. https://doi.org/10.3402/jmahp.v1i0.22799

Article Metrics

Back to TopTop